A New Phase in SMA Treatment: FDA Approves the First Gene-Replacement Therapy Applicable Across All Ages
The U.S. FDA has formally approved Novartis’ Itvisma (onasemnogene abeparvovec-brve) for use in children aged two and older, adolescents, and adults with spinal muscular atrophy (SMA).
This represents the first gene-replacement therapy expanded to all eligible age groups, marking a significant advancement in the field of genetic medicine.
Significance of the Approval in SMA Treatment
SMA is a rare neuromuscular disorder caused by mutations or deletions in the SMN1 gene.
It is estimated that approximately 9,000 individuals in the United States and around 1,500 in Japan are affected.
Among older children, teens, and adults, long-standing unmet needs have been widely recognized—particularly in motor neuron preservation and the maintenance of physical function.
With this approval, patients who previously relied largely on chronic maintenance therapies now gain access to a treatment that directly targets the genetic root cause of the disease.
Clinical Evidence Supporting Approval (STEER / STRENGTH)
• Statistically significant improvements in motor function
• Sustained effects over a 52-week follow-up period
• A consistent safety profile across all age groups
Itvisma is expected to become available in the United States beginning in December 2025.
Greenstaff Life Sciences’ Perspective
This regulatory milestone not only reflects progress in therapeutic approaches but also indicates a growing need for specialized talent across advanced biopharmaceutical development.
In particular, increased hiring and career opportunities are anticipated in the following domains:
• Gene Therapy and AAV technologies
• GMP manufacturing, QA/QC, and CMC
• Clinical development for rare and neuromuscular diseases
• Medical Affairs, Regulatory Affairs, and Drug Safety
• Global clinical operations and regulatory coordination
As gene therapy continues to advance toward broader clinical implementation, the demand for highly skilled life sciences professionals is expected to expand further.
Greenstaff Life Sciences remains committed to connecting companies and research institutions with the specialized talent essential for sustained progress in advanced therapeutics, rare diseases, and biopharmaceutical innovation.